newsfilter
← Latest News
GlobeNewswire·

Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback

HOUSTON, TX, May 01, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin"), today announced that it plans to submit a Q-Submission ("Q-Sub") to the U.S. Food and Drug